AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18326591 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (400 mg/d)
Number of subjects: 135
Study 18326591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 17142642 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic physical therapy for 6 weeks
Number of subjects: 71
Study 17142642 — intervention group
Group type: COMPARATOR
Intervention: No aquatic physical therapy (control)
Number of subjects: 71
Study 12945024 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 3-in-1 block
Number of subjects: 44
Study 12945024 — intervention group
Group type: COMPARATOR
Intervention: Continuous fascia iliaca compartment block
Number of subjects: 44
Study 11026748 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg Ginkgo biloba
Number of subjects: 20
Study 11026748 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg Ginkgo biloba
Number of subjects: 20
Study 11026748 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg Ginkgo biloba
Number of subjects: 20
Study 11026748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9062542 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose beta-carotene (0.5 mg/d) for days 1-60
Number of subjects: 9
Study 9062542 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid complex from vegetables rich in carotenoids on days 101-120
Number of subjects: 9
Study 9062542 — intervention group
Group type: COMPARATOR
Intervention: Placebo for days 1-60
Number of subjects: 9
Study 1306851 — intervention group
Group type: EXPERIMENTAL
Intervention: 50/50 EE (50 micrograms EE + 125 micrograms desogestrel)
Number of subjects: 0
Study 1306851 — intervention group
Group type: EXPERIMENTAL
Intervention: 40/30 EE (40 micrograms EE + 25 micrograms desogestrel)
Number of subjects: 0
Study 1306851 — intervention group
Group type: EXPERIMENTAL
Intervention: 50/50 EE
Number of subjects: 0
Study 1306851 — intervention group
Group type: EXPERIMENTAL
Intervention: 40/30 EE
Number of subjects: 0
Study 1306851 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 0
Study 1306851 — intervention group
Group type: COMPARATOR
Intervention: Control values (not specified)
Number of subjects: 0
Study 3000176 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbinil (250 mg daily for 6 weeks)
Number of subjects: 47
Study 3000176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 30280130 — intervention group
Group type: COMPARATOR
Intervention: Limited discectomy
Number of subjects: 278
Study 27649561 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (AL)
Number of subjects: 312
Study 27649561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DP)
Number of subjects: 312
Study 27649561 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (AL) and Dihydroartemisinin-Piperaquine (DP)
Number of subjects: 312
Study 23615480 — intervention group
Group type: EXPERIMENTAL
Intervention: Static 5-minute stretching
Number of subjects: 19
Study 23615480 — intervention group
Group type: COMPARATOR
Intervention: Control (no stretching)
Number of subjects: 19
Study 22327755 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation (n=28)
Number of subjects: 49
Study 22327755 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital treatment (n=21)
Number of subjects: 49
Study 20189552 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative adjective-noun phrases (e.g. blue car)
Number of subjects: 30
Study 20189552 — intervention group
Group type: COMPARATOR
Intervention: Control trials (uninformative adjective-noun phrases)
Number of subjects: 30
Study 20189552 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative adjective-noun phrases
Number of subjects: 30
Study 18341756 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fermented with Lactobacillus casei
Number of subjects: 104
Study 18341756 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 104
Study 15653967 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) exposure
Number of subjects: 17842
Study 15653967 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 17842
Study 15653967 — intervention group
Group type: EXPERIMENTAL
Intervention: Other ICS
Number of subjects: 17842
Study 15653967 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS exposure among patients with COPD only
Number of subjects: 17842
Study 12204459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation-compression ratio 1:5
Number of subjects: 14
Study 12204459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation-compression ratio 2:15
Number of subjects: 14
Study 12204459 — intervention group
Group type: COMPARATOR
Intervention: Both ratios (1:5 and 2:15)
Number of subjects: 14
Study 10325849 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular surgery
Number of subjects: 0
Study 10325849 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 0
Study 8953203 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 0
Study 8953203 — intervention group
Group type: COMPARATOR
Intervention: Oral treatment (sulfonylurea)
Number of subjects: 0
Study 1672588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent medication (given only when the patient shows early signs of relapse)
Number of subjects: 101
Study 1672588 — intervention group
Group type: COMPARATOR
Intervention: Moderate doses of maintenance medication
Number of subjects: 101
Study 1672588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent medication
Number of subjects: 101
Study 1672588 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention strategy
Number of subjects: 101
Study 7138951 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to decrease HR plus continuous negative (failure) binary feedback
Number of subjects: 16
Study 7138951 — intervention group
Group type: COMPARATOR
Intervention: Instructions to decrease HR only
Number of subjects: 16
Study 31281931 — intervention group
Group type: EXPERIMENTAL
Intervention: CRE colonisation and infections
Number of subjects: 2875
Study 31281931 — intervention group
Group type: EXPERIMENTAL
Intervention: Klebsiella pneumoniae
Number of subjects: 2875
Study 31281931 — intervention group
Group type: EXPERIMENTAL
Intervention: KPC-2-producing bacteria
Number of subjects: 2875
Study 31281931 — intervention group
Group type: COMPARATOR
Intervention: No underlying conditions
Number of subjects: 2875
Study 31281931 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary diseases
Number of subjects: 2875
Study 31281931 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics used prior to culture within 30 days
Number of subjects: 2875
Study 28304242 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab (150 mg subcutaneously every 2 weeks)
Number of subjects: 27438
Study 28304242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27438
Study 28304242 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab
Number of subjects: 27438
Study 25651842 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (ART) initiation
Number of subjects: 0
Study 25651842 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART initiation
Number of subjects: 0
Study 23777411 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of one deciduous canine
Number of subjects: 24
Study 23777411 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral side, no extraction)
Number of subjects: 24
Study 22908169 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 mg piperacillin
Number of subjects: 10
Study 22908169 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000 mg piperacillin
Number of subjects: 10
Study 22908169 — intervention group
Group type: COMPARATOR
Intervention: High-dose short-term infusions (6 g every 8 h)
Number of subjects: 10
Study 22908169 — intervention group
Group type: COMPARATOR
Intervention: Low-dose continuous infusions (6 g/day)
Number of subjects: 10
Study 19126633 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention (start of cancer treatment)
Number of subjects: 465
Study 19126633 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed intervention (8 weeks after starting treatment)
Number of subjects: 465
Study 19126633 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 465
Study 19126633 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention (for high-risk patients)
Number of subjects: 465
Study 19126633 — intervention group
Group type: COMPARATOR
Intervention: Usual care (for high-risk patients)
Number of subjects: 465
Study 19126633 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention (for low-risk patients)
Number of subjects: 465
Study 19126633 — intervention group
Group type: COMPARATOR
Intervention: Usual care (for low-risk patients)
Number of subjects: 465
Study 17407391 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous glatiramer acetate (SC GA)
Number of subjects: 0
Study 17407391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a (IM IFNbeta‐1a)
Number of subjects: 0
Study 17407391 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta-1a (SC IFNbeta‐1a)
Number of subjects: 0
Study 17407391 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta-1b (SC IFNbeta‐1b)
Number of subjects: 0
Study 17407391 — intervention group
Group type: COMPARATOR
Intervention: Symptom management alone
Number of subjects: 0
Study 15357164 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine ointment and gauze dressings
Number of subjects: 0
Study 15357164 — intervention group
Group type: COMPARATOR
Intervention: Transparent dressings alone (Control)
Number of subjects: 0
Study 11167352 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg cetirizine
Number of subjects: 18
Study 11167352 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg levocetirizine
Number of subjects: 18
Study 11167352 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg ucb 28557
Number of subjects: 18
Study 9745994 — intervention group
Group type: EXPERIMENTAL
Intervention: Profiled Hemodialysis (PHD)
Number of subjects: 12
Study 9745994 — intervention group
Group type: COMPARATOR
Intervention: Standard Hemodialysis (SHD)
Number of subjects: 12
Study 7833105 — intervention group
Group type: EXPERIMENTAL
Intervention: CEV (cyclophosphamide 1000 mg/m2 i.v., epirubicin 70 mg/m2 i.v., vincristine 1.2 mg/m2 i.v., every 3 weeks)
Number of subjects: 139
Study 7833105 — intervention group
Group type: COMPARATOR
Intervention: PE (cisplatin 20 mg/m2 i.v. and etoposide 75 mg/m2 i.v. for 5 consecutive days, every 3 weeks)
Number of subjects: 139
Study 3207526 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 30
Study 3207526 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 30
Study 3207526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 30
Study 3207526 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium
Number of subjects: 30
Study 3207526 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine
Number of subjects: 30
Study 29177605 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC4 + Clinical PathIES score
Number of subjects: 430
Study 29177605 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC4 score alone
Number of subjects: 430
Study 29177605 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical score (C) based on age, grade, tumour size and nodal status
Number of subjects: 430
Study 28051270 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal laparoscopic partial dissection of adipose renal capsule plus ligation of renal pedicle lymphatic vessels (Group A)
Number of subjects: 38
Study 28051270 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal laparoscopic complete dissection of adipose renal capsule plus ligation of renal pedicle lymphatic vessels (Group B)
Number of subjects: 38
Study 26149996 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir (LPV) treatment during pregnancy
Number of subjects: 208
Study 23957383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 338
Study 23957383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 23957383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 338
Study 23957383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Number of subjects: 338
Study 21348538 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 10 mg (Onglyza™)
Number of subjects: 0
Study 21348538 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg (2.5 mg orally once daily)
Number of subjects: 0
Study 21348538 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 0
Study 18469231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 47
Study 18469231 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 47
Study 16950285 — intervention group
Group type: EXPERIMENTAL
Intervention: Farm exposure in early life
Number of subjects: 600
Study 16950285 — intervention group
Group type: EXPERIMENTAL
Intervention: CD14-159TT genotype
Number of subjects: 600
Study 16950285 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of farm exposure and CD14-159TT genotype
Number of subjects: 600
Study 15062149 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy EBRT
Number of subjects: 91
Study 15062149 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 Gy EBRT
Number of subjects: 91
Study 15062149 — intervention group
Group type: EXPERIMENTAL
Intervention: Pd‐103 implantation
Number of subjects: 91
Study 15062149 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 91
Study 11467759 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 51
Study 11467759 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 51
Study 9575675 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer length alleles of the PEM gene in severe acne patients
Number of subjects: 0
Study 9575675 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 9575675 — intervention group
Group type: COMPARATOR
Intervention: Atopic dermatitis patients
Number of subjects: 0
Study 7827905 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative mechanical bowel preparation (group 1)
Number of subjects: 149
Study 7827905 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (group 2)
Number of subjects: 149
Study 3168339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium chloride (10 mmol in 100 ml isotonic sodium chloride)
Number of subjects: 9
Study 3168339 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic sodium chloride only)
Number of subjects: 9
Study 30929643 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching problem solving skills over six sessions of two hours each to the intervention group.
Number of subjects: 90
Study 30929643 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 90
Study 30929643 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching problem solving skills to the intervention group.
Number of subjects: 90
Study 29026903 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g freeze dried blueberry powder (WBB)
Number of subjects: 21
Study 29026903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 25335119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 2
Study 25335119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 23446667 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 492
Study 23446667 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC
Number of subjects: 492
Study 23446667 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy and CTC
Number of subjects: 492
Study 22088858 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day ezetimibe/simvastatin combination therapy
Number of subjects: 150
Study 22088858 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day atorvastatin
Number of subjects: 150
Study 22088858 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day rosuvastatin
Number of subjects: 150
Study 19442725 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactolycopene supplementation for 12 weeks
Number of subjects: 25
Study 19442725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 16355341 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir, 400 mg once daily plus efavirenz placebo
Number of subjects: 211
Study 16355341 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz, 600 mg once daily plus atazanavir placebo
Number of subjects: 211
Study 15053688 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiation of pitch durations within tone sequences
Number of subjects: 0
Study 15053688 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical organization of pitch distributions
Number of subjects: 0
Study 15053688 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiation of tonic from nontonic pitches
Number of subjects: 0
Study 10739509 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg/d
Number of subjects: 136
Study 10739509 — intervention group
Group type: COMPARATOR
Intervention: Continuous-combined hormone replacement therapy (conjugated equine estrogens 0.625 mg/d with medroxyprogesterone acetate 2.5 mg/d)
Number of subjects: 136
Study 9059215 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (1 MAC)
Number of subjects: 0
Study 9059215 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (1 MAC)
Number of subjects: 0
Study 9059215 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (1 MAC) and Isoflurane (1 MAC)
Number of subjects: 0
Study 7801591 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast media (CM)
Number of subjects: 90
Study 7801591 — intervention group
Group type: COMPARATOR
Intervention: Urografin (ionic CM)
Number of subjects: 90
Study 31912801 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI)
Number of subjects: 210
Study 31912801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 31001264 — intervention group
Group type: EXPERIMENTAL
Intervention: SjCTPI bovine vaccine (prime-boost regimen)
Number of subjects: 12
Study 31001264 — intervention group
Group type: EXPERIMENTAL
Intervention: Human mass chemotherapy (praziquantel)
Number of subjects: 12
Study 31001264 — intervention group
Group type: COMPARATOR
Intervention: Mollusciciding
Number of subjects: 12
Study 31001264 — intervention group
Group type: EXPERIMENTAL
Intervention: SjCTPI bovine vaccine
Number of subjects: 12
Study 27662321 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Time (TST)
Number of subjects: 208
Study 27662321 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Efficiency (SE)
Number of subjects: 208
Study 27662321 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of Awakenings
Number of subjects: 208
Study 27662321 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Disability (ADCS-ADL scores)
Number of subjects: 208
Study 27662321 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease Severity
Number of subjects: 208
Study 25538277 — intervention group
Group type: EXPERIMENTAL
Intervention: H3N2c cell‐culture‐derived vaccine with MF59 adjuvant
Number of subjects: 627
Study 25538277 — intervention group
Group type: COMPARATOR
Intervention: H3N2c cell‐culture‐derived vaccine without MF59 adjuvant
Number of subjects: 627
Study 25538277 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 µg + 0.25 mL MF59
Number of subjects: 627
Study 25538277 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59‐adjuvanted H3N2c vaccines
Number of subjects: 627
Study 23612700 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary ligation of the pulmonary artery (group A)
Number of subjects: 385
Study 23612700 — intervention group
Group type: COMPARATOR
Intervention: Primary ligation of the pulmonary vein (group V)
Number of subjects: 385
Study 22111718 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose budesonide (0.5 mg nightly)
Number of subjects: 278
Study 22111718 — intervention group
Group type: COMPARATOR
Intervention: Intermittent high-dose budesonide (1 mg twice daily for 7 days during respiratory illness)
Number of subjects: 278
Study 18953855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative facial nerve (NF) monitoring (Group FN)
Number of subjects: 70
Study 18953855 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of multiple nerves (trigeminal, glossopharyngeal, accessory, hypoglossal) (Group MN)
Number of subjects: 70
Study 18953855 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial neuromuscular relaxation maintained at train of four stimulation (TOF)=3 by continuous vencronium infusion
Number of subjects: 70
Study 16409339 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg morphine
Number of subjects: 60
Study 16409339 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 12932091 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus artesunate
Number of subjects: 536
Study 12932091 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine monotherapy
Number of subjects: 536
Study 11421382 — intervention group
Group type: EXPERIMENTAL
Intervention: HT-ETIG
Number of subjects: 134
Study 11421382 — intervention group
Group type: COMPARATOR
Intervention: ETIG
Number of subjects: 134
Study 11421382 — intervention group
Group type: EXPERIMENTAL
Intervention: HT-ETIG and ETIG
Number of subjects: 134
Study 9273226 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) and interleukin-8 (IL-8) measured in bronchoalveolar lavage fluid
Number of subjects: 32
Study 9273226 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 subjects)
Number of subjects: 32
Study 1515386 — intervention group
Group type: EXPERIMENTAL
Intervention: 17.5 ml mepivacaine
Number of subjects: 16